Therapeutic Area | MeSH |
---|---|
hemic and lymphatic diseases | D006425 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Gamifant | emapalumab-lzsg | Orphan Medical | N-761107 RX | 2018-11-20 | 3 products |
Brand Name | Status | Last Update |
---|---|---|
gamifant | Biologic Licensing Application | 2024-10-04 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hemophagocytic lymphohistiocytosis | — | D051359 | D76.1 |
Expiration | Code | ||
---|---|---|---|
emapalumab, Gamifant, Swedish Orphan Biovitrum AB (publ) | |||
2025-11-20 | Orphan excl. |
Code | Description |
---|---|
J9210 | Injection, emapalumab-lzsg, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | 4 | 5 | 1 | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Macrophage activation syndrome | D055501 | EFO_1001806 | — | — | 1 | 1 | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | — | 1 |
Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | — | — | 1 |
Disease | D004194 | EFO_0000408 | R69 | — | — | 1 | — | — | 1 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Graft rejection | D006084 | — | — | — | 1 | — | — | — | 1 |
Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 1 | — | — | — | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Adult-onset still's disease | D016706 | EFO_0007135 | M06.1 | — | 1 | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | — | 1 | — | — | — | 1 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
B-cell lymphoma | D016393 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rare diseases | D035583 | — | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Emapalumab |
INN | elenbecestat |
Description | Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1709815-23-5 |
RxCUI | — |
ChEMBL ID | CHEMBL3989977 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB14724 |
UNII ID | RXJ96XL94H (ChemIDplus, GSRS) |